| 1. |
National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version). Chin J Cancer Res, 2019, 31(5): 707-737.
|
| 2. |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
|
| 3. |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
|
| 4. |
王童博, 毛啟坤, 張曉杰, 等. 新輔助治療行胃癌根治術患者術后并發癥及其對預后的影響因素分析. 中華胃腸外科雜志, 2021, 24(2): 160-166.
|
| 5. |
葉建新, 劉聲源, 莊金福. 新輔助化療對進展期胃癌手術并發癥的影響. 腫瘤防治研究, 2014, 41(9): 1026-1030.
|
| 6. |
江良縣, 周申康, 劉帥, 等. 新輔助化療聯合腹腔鏡手術治療進展期胃癌效果及患者生活質量情況觀察. 世界華人消化雜志, 2018, 26(13): 782-789.
|
| 7. |
范朝剛, 李國立. 新輔助化療對進展期胃癌患者術后肺部感染的影響. 中華胃腸外科雜志, 2011, 14(7): 503-505.
|
| 8. |
Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol, 2010, 28(35): 5210-5218.
|
| 9. |
An JY, Kim KM, Kim YM, et al. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. Ann Surg Oncol, 2012, 19(8): 2452-2458.
|
| 10. |
Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol, 2007, 14(7): 2010-2017.
|
| 11. |
van der Wielen N, Straatman J, Daams F, et al. Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial. Gastric Cancer, 2021, 24(1): 258-271.
|
| 12. |
Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg, 2019, 154(12): 1093-1101.
|
| 13. |
Hayashi M, Yoshikawa T, Yura M, et al. Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study. BMC Surg, 2020, 20(1): 150.
|
| 14. |
Xing J, Wang Y, Shan F, et al. Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer. Eur J Surg Oncol, 2021 Feb 6, Online ahead of print.
|
| 15. |
沈國杰, 朱侃愷, 鄔一軍, 等. 新輔助化療聯合胃癌根治術治療進展期胃癌的臨床療效. 中華消化外科雜志, 2017, 16(3): 240-244.
|
| 16. |
Li ZY, Shan F, Zhang LH, et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol, 2011, 9: 110.
|
| 17. |
崔昊, 張珂誠, 曹博, 等. 進展期胃癌新輔助化療患者全胃切除術后并發癥影響因素分析. 中華胃腸外科雜志, 2021, 24(2): 153-159.
|
| 18. |
Valenti V, Hernandez-Lizoaín JL, Beorlegui MC, et al. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol, 2011, 104(2): 124-129.
|
| 19. |
Wu C, Wang N, Zhou H, et al. Effects of neoadjuvant chemotherapy toxicity and postoperative complications on short-term and long-term outcomes after curative resection of gastric cancer. J Gastrointest Surg, 2020, 24(6): 1278-1289.
|
| 20. |
Yang SJ, Li HR, Zhang WH, et al. Visceral fat area (VFA) superior to BMI for predicting postoperative complications after radical gastrectomy: a prospective cohort study. J Gastrointest Surg, 2020, 24(6): 1298-1306.
|
| 21. |
楊昆, 張維漢, 陳心足, 等. 新輔助治療大體組織反應評級體系的建立和初步應用. 中華胃腸外科雜志, 2018, 21(9): 1032-1038.
|
